跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT03706209
NCT03706209已完成2 期

A Phase II, Multicenter, Double-blind, Placebo-controlled, Efficacy and Safety Trial of Two Oral Doses (150 mg Bid / 300 mg Bid) of MP1032 in Male and Female Patients With Moderate-to-Severe Chronic Plaque Psoriasis

MetrioPharm AG19 个研究点 分布在 2 个国家目标入组 155 人开始时间: 2018年2月27日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
155
试验地点
19
主要终点
PASI 75 - Week 12 (EoT)
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The primary objective of this trial is to evaluate the clinical efficacy and safety of two oral doses of MP1032 (150 mg bid and 300 mg bid) when taken for 12 weeks by patients with moderate-to-severe chronic plaque psoriasis.

详细描述

This trial is a randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy and safety of two oral doses of MP1032 (150 mg bid and 300 mg bid) in adult patients with moderate-to-severe chronic plaque psoriasis.

The trial design consists of a 28-day screening period, a 12-week treatment period, and subsequently a 28-day follow-up period. Each patient will have 6 visits and unscheduled visits as needed.

Approximately 150 patients (2 × 50 patients MP1032 and 50 patients placebo) who meet the entry criteria will be randomized on Day 1 to receive either 150 mg MP1032, 300 mg MP1032 or placebo orally twice daily for 12 weeks. The administration of IMP will stop after end of study (in max. 13 weeks).

PASI (Psoriasis Area and Severity Index), PGA (Physician Global Assessment) and BSA (Body Surface Area) Scores will be recorded at predefined timepoints as basis for the efficacy evaluation.

Safety parameter will be monitored from the signing of the informed consent form (ICF) until the last follow-up visit.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

double-blind

入排标准

年龄范围
18 Years 至 70 Years（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •Participants legally competent to sign and give informed consent.
  • •Adult male and female patients between 18 years and 70 years with moderate-to-severe chronic plaque psoriasis (diagnosed by Investigator):
  • •PASI score ≥10 - ≤20 at baseline
  • •BSA score: > 10%
  • •Stable disease duration of ≥ 6 months at the initiation of IMP.
  • •topical therapy fails to control the disease
  • •Body Mass Index (BMI) between 18.5 and 34.9 kg/m
  • •Women of childbearing potential (WCBP) must have a negative serum pregnancy test at Screening (Visit 1). In addition, sexually active WCBP must agree to use adequate contraception throughout the trial (see Section 3.2 for more details on adequate contraception):
  • •A method with less than 1% failure rate OR
  • •Post-menopausal women with spontaneous amenorrhea for at least 12 months and women on hormonal replacement therapy (HRT). The use of hormonal replacement therapy (HRT) during the trial is permitted, however for these patients an appropriate contraception method according to Inclusion Criterion 4 must be ensured. Sterilized women may be included (see Section 3.2 for more details on sterile definition)
  • •Male patients who are sexually active with a female partner and are not surgically sterile (vasectomy performed at least six months prior to treatment) must agree to inform their female sexual partner to use an acceptable form of birth control as described in the informed consent form. For females, an acceptable method (Pearl Index < 1%) would be to use implants, injectable, combined oral contraceptives, some intrauterine devices, or be postmenopausal, be surgically sterile (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy)
  • •In good health as judged by the investigator, based on medical history, physical examination, serum chemistry, hematology and urinalysis
  • •Patients must meet the following clinical laboratory criteria:
  • •White blood cell count ≥3.5 × 109/L
  • •Platelet count ≥100 × 109/L
  • •Serum creatinine ≤1.5 × upper limit of normal (ULN); estimated glomerular filtration rate >60 mL/min
  • •Total bilirubin ≤1.5 × ULN
  • •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN
  • •Hemoglobin ≥ lower limit of normal as per central laboratory reference ranges for women and men accordingly
  • •No coagulopathy (International Normalized Ratio [INR] <1.5)
  • •Patients agree to minimize normal sun exposure during the course of the trial
  • •Patients are considered reliable and capable of adhering to the protocol (e.g. able to understand the patient information and complete diaries), visit schedule, or medication intake according to the judgment of the Investigator.

排除标准

  • •Patients with non-plaque form of psoriasis (erythrodermic, guttate, pustular form of psoriasis). Associated psoriasis arthritis is allowed provided no other in-/exclusion criteria are influenced, no forbidden concomitant therapy is required for the well -being of the patient and there is no impact on trial objectives as determined by the Investigator.
  • •Treatment with concomitant medication that may affect and provoke or aggravate psoriasis, e.g. antimalarial drugs, beta-blockers or ACE (angiotensin-converting-enzyme) inhibitors unless on a stable dose for 3 months before IMP intake.
  • •Evidence of skin conditions at the time of Screening Visit other than psoriasis that would interfere with evaluations of the effect of the IMP on psoriasis.
  • •Patients with any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from signing the ICF, as assessed by the investigator.
  • •Pregnant or lactating women or women planning to become pregnant during the trial and / or within 28 days following the last dose of IMP.
  • •Male patients planning a partner pregnancy or sperm donation during the trial including follow up period.
  • •Known allergies to any ingredient of the IMP e.g. mannitol, macrophage modulators, or gelatin.
  • •History or symptoms of a clinically significant illness in the four weeks before first treatment and during the trial that in the opinion of the investigator may place the patient at risk by trial participation or influence the outcome of the trial. Well controlled diseases such as hypertension, hyperlipidemia, diabetes or hypothyroidism are permitted.
  • •Patients with active malignancy or history of malignancy, except for basal cell and actinic keratosis. Basal cell carcinoma of the skin or in situ cervical carcinoma that have been fully treated and show no evidence of recurrence are allowed.
  • •Positive HIV-Antibody, HBs-Antigen or HCV-Antibody-Test at screening.
  • •Previous strong sun exposure (e.g. sea holiday) within 28 days or UV treatment within 24 weeks before IMP initiation.
  • •Known photo allergy and / or experienced drug-induced photo toxicity.
  • •Elective (planned) hospitalization or medical intervention preventing patient from following the protocol requirements.
  • •Prior treatment not adhering to defined drug classes and related washout periods (Protocol table 2.)
  • •Planned use of any ultraviolet (UV) phototherapy or photochemotherapy / photosensitizing drugs during the course of the trial and within 28 days/24 weeks following the last dose of the IMP.
  • •Patients with a history of chronic alcohol or drug abuse within 6 months of IMP initiation.
  • •Patients with a blood pressure outside the given range of 160 mm Hg (systolic) and 95 mm Hg (diastolic)
  • •Patients who are employed by MetrioPharm, contract research organization (CRO) or clinical site involved in the clinical trial.
  • •Vulnerable patients (e.g. patients kept in detention).
  • •Patients who are unable to communicate, read or understand the local language, or who display another condition, which, in the Investigator's opinion, makes them unsuitable for clinical trial participation.
  • •Patient is institutionalized because of legal or regulatory order.

研究组 & 干预措施

Placebo bid

Placebo Comparator

6 × placebo hard gelatin capsules (per dosage) are provided twice daily over a period of 12 weeks.

干预措施: Placebo (Drug)

150 mg MP1032 bid

Experimental

3 × 50 mg (150 mg) MP1032 plus 3 × placebo hard gelatin capsules (per dosage) are provided twice daily over a period of 12 weeks.

干预措施: MP1032 (Drug)

150 mg MP1032 bid

Experimental

3 × 50 mg (150 mg) MP1032 plus 3 × placebo hard gelatin capsules (per dosage) are provided twice daily over a period of 12 weeks.

干预措施: Placebo (Drug)

300 mg MP1032 bid

Experimental

6 × 50 mg (300 mg) MP1032 hard gelatin capsules (per dosage) are provided twice daily over a period of 12 weeks.

干预措施: MP1032 (Drug)

结局指标

主要结局

PASI 75 - Week 12 (EoT)

时间窗: Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up)

Percentage of patients reaching PASI 75 in treatment groups (150 and 300 mg bid) compared to placebo. The PASI (psoriasis area severity index) is the most commonly used and validated assessment for grading the severity of psoriasis in clinical studies and combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease) wherein any value higher than 10 is considered as moderate to severe psoriasis. The number of responders corresponds to the number of patients with an improvement of at least 75% in the PASI score at End-of-Treatment (EoT) compared to baseline.

PGA Improvement - Week 12 (EoT)

时间窗: Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up)

PGA improvement rate in treatment groups (150 and 300 mg bid) compared to placebo. The PGA (Physician's global assessment) provides an overall evaluation of the severity of the disease ranging from 0 (clear skin - no diseases) to 6 (severe disease). The number of responders corresponds to the number of patients with an improvement of 1 or more points on the 7-points PGA scale at End-of-Treatment (EoT) compared to baseline.

次要结局

  • PASI 75 VCS - Week 12 (EoT)(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PGA Improvement VCS - Week 12 (EoT)(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PASI 50 - Week 12 (EoT)(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PASI ANCOVA Change From Baseline - Week 12 (EoT)(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PASI Descriptive Statistics - Week 12 (EoT)(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • Time to PASI 75(from treatment start (Study Day 1 - Baseline) to either Study Day 25, 56, 84 (EoT) or 112 (FU))
  • Time to PASI 50(from treatment start (Study Day 1 - Baseline) to either Study Day 25, 56, 84 (EoT) or 112 (FU))
  • PGA Descriptive Statistics - Week 12 (EoT)(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PGA Frequency Counts - Week 12 (EoT)(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • BSA Descriptive Statistics - Week 12 (EoT)(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PASI 75 - Week 4(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PASI 75 - Week 8(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PASI 75 - Week 16 (FU)(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PASI 50 - Week 4(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PASI 50 - Week 8(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PASI 50 - Week 16 (FU)(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PASI ANCOVA Change From Baseline - Week 4(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PASI ANCOVA Change From Baseline - Week 8(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PASI ANCOVA Change From Baseline - Week 16 (FU)(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PASI Descriptive Statistics - Week 4(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PASI Descriptive Statistics - Week 8(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PASI Descriptive Statistics - Week 16 (FU)(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PGA Improvement - Week 4(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PGA Improvement - Week 8(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PGA Improvement - Week 16 (FU)(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PGA Descriptive Statistics - Week 4(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PGA Descriptive Statistics - Week 8(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PGA Descriptive Statistics - Week 16 (FU)(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PGA Frequency Counts - Day 1 (Baseline)(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PGA Frequency Counts - Week 4(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PGA Frequency Counts - Week 8(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PGA Frequency Counts - Week 16 (FU)(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • BSA Descriptive Statistics - Week 4(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • BSA Descriptive Statistics - Week 8(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • BSA Descriptive Statistics - Week 16 (FU)(Scoring took place on Site visits: Day1 (Baseline), Week 4, Week 8, Week 12 (End-of-Treatment), Week 16 (Follow-Up))
  • PK Data - Cmax(Morning dose on Study Day 1)
  • PK Data - Tmax(Morning dose on Study Day 1)
  • PK Data - AUC(0,t)(Morning dose on Study Day 1)
  • Number of Patients With TEAEs(Overall Trial - Explicit inquiry on Day1, Week 4, Week 8, Week 12 (EoT), Week 16 (Follow Up))
  • Number of Patients With Serious TEAEs(Overall Trial - Explicit inquiry on Day1, Week 4, Week 8, Week 12 (EoT), Week 16 (Follow Up))
  • Number of Patients With TEAEs Leading to Study Discontinuation(Overall Trial - Explicit inquiry on Day1, Week 4, Week 8, Week 12 (EoT), Week 16 (Follow Up))
  • Number of Patients With TEAEs by SOC(Overall Trial - Explicit inquiry on Day1, Week 4, Week 8, Week 12 (EoT), Week 16 (Follow Up))
  • Number of Patients With TEAEs by Intensity(Overall Trial - Explicit inquiry on Day1, Week 4, Week 8, Week 12 (EoT), Week 16 (Follow Up))
  • Number of Patients With TEAEs by Relation to the IMP(Overall Trial - Explicit inquiry on Day1, Week 4, Week 8, Week 12 (EoT), Week 16 (Follow Up))
  • Number of Patients With TEAEs by Causality With the IMP(Overall Trial - Explicit inquiry on Day1, Week 4, Week 8, Week 12 (EoT), Week 16 (Follow Up))
  • Extent of Exposure - Dosed Capsules(overall trial / treatment period - cumulative from baseline to week 12 (EoT) or - if applicable - week16 (FU))
  • Extent of Exposure - Capsules Per Application(overall trial / treatment period - from baseline to week 12 (EoT) or - if applicable - week16 (FU))
  • Extent of Exposure - Capsules Per Day(overall trial / treatment period - from baseline to week 12 (EoT) or - if applicable - week16 (FU))
  • Sufficient Extent of Exposure(overall trial / treatment period - cumulative from baseline to week 12 (EoT) or - if applicable - week16 (FU))
  • Extent of Exposure - Treatment Duration(overall trial / treatment period - cumulative from baseline to week 4, 8, 12 (EoT), and - if applicable - week16 (FU))

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (19)

Loading locations...

相似试验

终止
2 期
A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1Cystic Fibrosis
NCT04059094Boehringer Ingelheim52
已完成
2 期
A Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic RhinitisSeasonal Allergic Rhinitis
NCT00407927Merck Sharp & Dohme LLC571
已完成
3 期
Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental PainPain, Postoperative
NCT01280591Bayer712
已完成
1 期
Multicenter Clinical Trial for the Evaluation of Mesenchymal Stem Cells From Adipose Tissue in Patients With Chronic Graft Versus Host Disease.Graft Versus Host DiseaseChronic and Expanded Graft Versus Host DiseaseImmune System Diseases
NCT01222039Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud19
已完成
2 期
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective DisorderTardive Dyskinesia
NCT01393600Neurocrine Biosciences37